Opinion|Videos|January 15, 2025
Coordinating Care for Patients with Advanced EGFR-Mutant NSCLC: A Multidisciplinary Approach
Panelists discuss the typical approach to coordinating care for lung cancer patients, highlighting the involvement of various healthcare professionals and the coordination efforts to optimize the patient journey from diagnosis through treatment and follow-up, with Julia explaining her role as a nurse in the multidisciplinary care of advanced breast cancer.
Advertisement
Video content above is prompted by the following:
- What is the typical approach to coordination of care for patients with lung cancer at your institution?
- Which healthcare professionals are typically involved?
- How are their efforts coordinated to optimize the patient journey, from diagnosis through treatment and follow-up?
- Describe your role as a nurse in the multidisciplinary treatment of advanced breast cancer.
- Upon referral, what were your thoughts when considering your treatment options?
- What questions or concerns did you have for him and his care team?
- What specific worries or anxieties were at the forefront of your mind?
- Once Melinda was referred to your office, what steps did you take to evaluate and confirm diagnosis of EGFR-mutant NSCLC?
Advertisement
Related to this article
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Ayal Aizer, MD, MHS, explains why fractionated SRS outperformed single-fraction SRS for surgical bed control in Alliance A071801.
Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.
“To me, the biggest differentiator might be how the patient wants to experience care,” said Krish Patel, MD, on treatment options for patients with lymphoma.
Ayal Aizer, MD, MHS, says Alliance A071801 supports fractionated SRS as standard after resection, with comparable radiation necrosis rates.
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
2
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
3
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
4
How Oncologists Can Navigate Patient Requests for Medical Aid in Dying
5